AB Science Reports Reduced Deficit and Clinical Progress

Ab Science ( (ABSCF) ) has released its Q4 earnings. Here is a breakdown of the information Ab Science presented to its investors.

AB Science is a pharmaceutical company specializing in the research, development, and commercialization of protein kinase inhibitors, focusing on diseases with high unmet medical needs. The company recently reported a significant reduction in its operating deficit for 2024, alongside updates on its clinical development programs. Key highlights include a 55% decrease in operating deficit, positive results from a phase 2 study of masitinib in COVID-19, and updates on the development of masitinib for multiple sclerosis and amyotrophic lateral sclerosis. The company also strengthened its intellectual property portfolio across various indications. Looking ahead, AB Science remains committed to advancing its clinical programs and exploring new opportunities in its targeted therapeutic areas.